Literature DB >> 21886652

Ceftobiprole: First reported experience in osteomyelitis.

A Macdonald1, G Dow.   

Abstract

A 74-year-old man with long-standing diabetes presented with advanced infection of the right forefoot associated with septic arthritis and osteomyelitis involving the second and third metatarsophalangeal joints. Polymicrobial infection, which included methicillin-resistant Staphylococcus aureus, was documented. First-line antibiotic therapy, which included vancomycin, was not tolerated. A durable cure was obtained following a six-week course of intravenous ceftobiprole medocaril combined with local surgery. The present report is the first to administer intravenous ceftobiprole medocaril to a patient with methicillin-resistant S aureus-associated septic arthritis and osteomyelitis.

Entities:  

Keywords:  Ceftobiprole; Diabetic foot; Osteomyelitis

Year:  2010        PMID: 21886652      PMCID: PMC2951809          DOI: 10.1155/2010/296760

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN: 1712-9532            Impact factor:   2.471


  20 in total

1.  Diagnosis and treatment of diabetic foot infections.

Authors:  Benjamin A Lipsky; Anthony R Berendt; H Gunner Deery; John M Embil; Warren S Joseph; Adolf W Karchmer; Jack L LeFrock; Daniel P Lew; Jon T Mader; Carl Norden; James S Tan
Journal:  Clin Infect Dis       Date:  2004-09-10       Impact factor: 9.079

2.  Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin.

Authors:  Tatiana Bogdanovich; Lois M Ednie; Stuart Shapiro; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

3.  Vancomycin concentrations in infected and noninfected human bone.

Authors:  A L Graziani; L A Lawson; G A Gibson; M A Steinberg; R R MacGregor
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

4.  [Highly resistant pathogens in patients with diabetic foot syndrome with special reference to methicillin-resistant Staphylococcus aureus infections].

Authors:  A Wagner; H Reike; B Angelkort
Journal:  Dtsch Med Wochenschr       Date:  2001-11-30       Impact factor: 0.628

5.  Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model.

Authors:  Li-Yan Yin; Luca Lazzarini; Fan Li; C Melinda Stevens; Jason H Calhoun
Journal:  J Antimicrob Chemother       Date:  2005-04-27       Impact factor: 5.790

6.  Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria.

Authors:  Gary J Noel; Richard S Strauss; Karen Amsler; Markus Heep; Rienk Pypstra; Joseph S Solomkin
Journal:  Antimicrob Agents Chemother       Date:  2007-10-22       Impact factor: 5.191

7.  Linezolid in the treatment of osteomyelitis: results of compassionate use experience.

Authors:  C R Rayner; L M Baddour; M C Birmingham; C Norden; A K Meagher; J J Schentag
Journal:  Infection       Date:  2004-02       Impact factor: 3.553

8.  Efficacies of ceftobiprole medocaril and comparators in a rabbit model of osteomyelitis due to methicillin-resistant Staphylococcus aureus.

Authors:  Li-Yan Yin; Jason H Calhoun; Jacob K Thomas; Stuart Shapiro; Anne Schmitt-Hoffmann
Journal:  Antimicrob Agents Chemother       Date:  2008-03-10       Impact factor: 5.191

9.  Clinical experience with daptomycin for the treatment of patients with osteomyelitis.

Authors:  Kenneth C Lamp; Lawrence V Friedrich; Luke Mendez-Vigo; Rene Russo
Journal:  Am J Med       Date:  2007-10       Impact factor: 4.965

10.  A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections.

Authors:  Gary J Noel; Karen Bush; Partha Bagchi; Juliana Ianus; Richard S Strauss
Journal:  Clin Infect Dis       Date:  2008-03-01       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.